Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RORB | Q92753 | 2/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31228833 | 0.98 | BCAT2 (0.96) | BCAT2KMT2ARXFP1ALDH1A1TSHR | |
| SCHEMBL9121778 | 0.84 | BCAT2 (0.72) | BCAT2KMT2ARXFP1ALDH1A1TSHR | |
| SCHEMBL1670982 | 0.84 | BCAT2 (0.72) | BCAT2KMT2ARXFP1ALDH1A1TSHR | |
| Oxalic Acid SCHEMBL27447145 | 0.82 | BCAT2 (0.70) | BCAT2KMT2ARXFP1ALDH1A1TSHR | |
| SCHEMBL2231308 | 0.81 | BCAT2 (0.69) | BCAT2KMT2AALDH1A1TSHRL3MBTL1 | |
| SCHEMBL6667283 | 0.81 | BCAT2 (0.69) | BCAT2ALDH1A1IKBKBHPGDPTGS1 | |
| SCHEMBL27353967 | 0.81 | BCAT2 (0.69) | BCAT2IKBKBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6669302 | 0.81 | BCAT2 (0.68) | BCAT2ALDH1A1IKBKBCYP1A2CYP3A4 | |
| SCHEMBL30423537 | 0.81 | BCAT2 (0.68) | BCAT2ALDH1A1RORBIKBKBCYP1A2 | |
| SCHEMBL8084435 | 0.81 | BCAT2 (0.68) | BCAT2KMT2ARXFP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108976172-A | A kind of 4- pyrimidinediamine micromolecular organic compound and its derivative and its application | 华东师范大学 | 2018-12-11 | — | — | CN | claimed |
| CN-1414965-A | Sulfonamides and derivatives thereof that modulate the activeity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 2003-04-30 | — | — | CN | claimed |
| WO-2025151311-A1 | NICOTINAMIDE DERIVATIVES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2023028117-A1 | METHODS OF TREATING CDGSH IRON SULFUR DOMAIN 2 INSUFFICIENCY-ASSOCIATED DISORDERS | YEH, TENG-KUANG (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-108976172-A | A kind of 4- pyrimidinediamine micromolecular organic compound and its derivative and its application | 华东师范大学 | 2018-12-11 | — | — | CN | disclosed |
| CN-108863832-A | A kind of preparation method of N- arylamides | 河南大学 | 2018-11-23 | — | — | CN | disclosed |
| US-8906899-B2 | Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2681205-A1 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS | Universität des Saarlandes (DE) | 2014-01-08 | — | — | EP | disclosed |
| US-20130303513-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-8501726-B2 | Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2012117097-A1 | BIARYL DERIVATIVES AS SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2 INHIBITORS | Universität des Saarlandes (DE) | 2012-09-07 | — | — | WO | disclosed |
| US-20120142663-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| CN-100471853-C | Phenyl-thiophene type vitamin D receptor modulators | LILLY CO ELI (US) | 2009-03-25 | — | — | CN | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| CN-1656089-A | Phenyl-thiophene type vitamin D receptor modulators | LILLY CO ELI (US) | 2005-08-17 | — | — | CN | disclosed |
| CN-1414965-A | Sulfonamides and derivatives thereof that modulate the activeity of endothelin | TEXAS BIOTECHNOLOGY CORP (US) | 2003-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | BCAT2 3816/4885KMT2A 3992/4885RXFP1 181/4885 |
| US-20130303513-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | BCAT2 4874/4885KMT2A 3390/4885RXFP1 191/4885 |
| US-20120142663-A1 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR2, S1PR5 | BCAT2 4874/4885KMT2A 3390/4885RXFP1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.